Cellebrite DI Ltd.

NasdaqGS:CLBT Voorraadrapport

Marktkapitalisatie: US$3.2b

Cellebrite DI Inkomsten in het verleden

Verleden criteriumcontroles 3/6

De winst van Cellebrite DI is gedaald met een gemiddeld jaarlijks percentage van -39.1%, terwijl de winst van de Software -industrie jaarlijks groeide met 21.4%. De inkomsten zijn groeide met een gemiddeld percentage van 17.1% per jaar. Het rendement op het eigen vermogen Cellebrite DI bedraagt 16.2% en de nettomarge bedraagt 16.4%.

Belangrijke informatie

-39.06%

Groei van de winst

-39.95%

Groei van de winst per aandeel

Software Groei van de industrie17.33%
Inkomstengroei17.06%
Rendement op eigen vermogen16.17%
Nettomarge16.36%
Volgende winstupdate14 May 2026

Recente prestatie-updates uit het verleden

Recent updates

CLBT: Updated Risk Profile And 2026 Guidance Will Support Premium P/E Potential

Analysts have trimmed their price targets on Cellebrite DI by $2. This reflects updated views on the stock's risk profile and valuation assumptions, while core growth and margin expectations remain largely unchanged.

CLBT: Updated Modeling And 2026 Guidance Will Support Premium P/E Potential

Cellebrite DI's analyst price targets have been trimmed by $2, with analysts linking the adjustment to updated assumptions around the discount rate, long term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts trimming their price targets by $2 are tying the move to refreshed views on discount rates, long term revenue growth, profit margins, and future P/E assumptions, rather than a single company specific event.

Cellebrite: A Rare SaaS Play Where AI Is A Tailwind, Not A Threat

Apr 06

CLBT: Refined Modeling And 2026 Guidance Will Support Premium P/E Potential

Analysts trimmed their price targets for Cellebrite DI by $2 to $21.67, citing updated assumptions on discount rate, long term revenue growth, profit margin and future P/E. These changes keep fair value broadly unchanged while slightly adjusting the risk and return profile.

CLBT: 2026 Revenue Guidance Will Support Earnings Power Despite P/E Recalibration

Analysts have trimmed their price targets on Cellebrite DI by $2, reflecting updated views on the stock's future P/E multiple and risk profile, while keeping key growth and profitability assumptions largely unchanged. Analyst Commentary Recent research updates suggest that analysts are adjusting their views on Cellebrite DI more around valuation mechanics than around its underlying business assumptions.

CLBT: Sustained Margins And 2026 Guidance Will Support Earnings Power

Analysts have adjusted their average price target on Cellebrite DI to about $21.67, down from the previous $24.71 level. The revised target reflects updated views on fair value, profit margins and future P/E assumptions following recent research updates from multiple firms.

CLBT: Higher Profitability Assumptions Will Support Stronger Medium Term Earnings Power

Analysts have raised their price target on Cellebrite DI from US$18.00 to US$23.00, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E as the key drivers of the change. What's in the News Cellebrite DI issued earnings guidance for the fourth quarter of 2025, with expected revenue between US$123 million and US$128 million and annual growth guidance of 13% to 17% (company guidance).

CLBT: Sustained Margins And 2025 ARR Guidance Will Support Earnings Power

Analysts have maintained their price target on Cellebrite DI at US$24.71, with only minor tweaks to inputs such as the discount rate and forward P/E, reflecting stable expectations around revenue growth and profit margin assumptions. What's in the News Cellebrite DI issued earnings guidance for the fourth quarter of 2025, targeting revenue of US$123 million to US$128 million, with annual growth of 13% to 17% (company guidance).

Cellebrite DI Ltd.'s (NASDAQ:CLBT) Shareholders Might Be Looking For Exit

Jan 13
Cellebrite DI Ltd.'s (NASDAQ:CLBT) Shareholders Might Be Looking For Exit

CLBT: Sustained Margin Strength Will Support Future Earnings Power

Analysts have maintained their fair value estimate for Cellebrite DI at US$24.71, making only minor adjustments to inputs such as the discount rate and long term P/E assumptions. This reflects a view that recent information does not materially alter their price outlook.

CLBT: Expanding Margins Will Support Stronger Earnings Power Ahead

Narrative Update on Cellebrite DI Analysts have modestly raised their price target on Cellebrite DI to approximately $24.71 per share, citing incremental improvements in the company’s discount rate assumptions and sustained expectations for high revenue growth and robust profit margins. What's in the News Cellebrite DI issued fourth quarter 2025 revenue guidance of $123 million to $128 million, implying year over year growth of 13% to 17% (company guidance).

CLBT: Expanding Margins Will Support Stronger Earnings Power Ahead

Narrative Update on Cellebrite DI Analysts have modestly raised their price target on Cellebrite DI to approximately $24.71 per share, reflecting slightly higher long term revenue growth and profit margin expectations that more than offset a marginally higher assumed discount rate and a modestly lower future P/E multiple. What's in the News Cellebrite DI issued revenue guidance for the fourth quarter of 2025, projecting between $123 million and $128 million, representing annual growth of 13% to 17% (company guidance).

CLBT: Profit Margins Will Drive Improved Earnings Outlook Into Next Year

Analysts have raised their price target for Cellebrite DI from $23.14 to $24.71. This change reflects increased confidence in the company’s stronger profit margins and revenue growth outlook.

Cloud SaaS Solutions Will Drive Digital Forensics Adoption

Cellebrite DI’s consensus price target was modestly raised to $23.14 as analysts anticipate near-term revenue softness due to U.S. federal budget constraints and delayed deal timing, while seeing future upside from eventual deal catch-up and FedRAMP progress. Analyst Commentary Slower-moving Q1 deals in Europe were completed in Q2, but persistent softness in U.S. federal deals is expected to continue until at least October, impacting near-term revenue.

What Cellebrite DI Ltd.'s (NASDAQ:CLBT) 26% Share Price Gain Is Not Telling You

Sep 09
What Cellebrite DI Ltd.'s (NASDAQ:CLBT) 26% Share Price Gain Is Not Telling You

Earnings Beat: Cellebrite DI Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 18
Earnings Beat: Cellebrite DI Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Cloud SaaS Solutions Will Drive Digital Forensics Adoption

Cellebrite DI’s consensus price target held steady at $23.00 as analysts factor in near-term headwinds from delayed federal spending and efficiency impacts, yet remain positive about long-term growth driven by healthy demand and anticipated federal certifications. Analyst Commentary Lowered Q2 results and second half guidance due to ongoing efficiency impacts and customer budget pauses.
User avatar

Cloud-Ready AI And Inseyets Migration Will Expand Digital Capabilities

Shift to cloud-based AI platforms and expansion in digital investigations are set to boost revenue through subscription services and high-margin solutions.

Cellebrite DI: A Compounder But Not Yet Priced For Conviction Buy

Apr 24

Cellebrite DI Ltd. (NASDAQ:CLBT) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 16
Cellebrite DI Ltd. (NASDAQ:CLBT) Analysts Are Pretty Bullish On The Stock After Recent Results

Cellebrite DI: Attractive Company In Connection With AI And Digital Investigation

Feb 04

A Look At The Intrinsic Value Of Cellebrite DI Ltd. (NASDAQ:CLBT)

Jan 10
A Look At The Intrinsic Value Of Cellebrite DI Ltd. (NASDAQ:CLBT)

Cellebrite: There Are Potential Risks That Could Damper Growth

Nov 08

Is There Now An Opportunity In Cellebrite DI Ltd. (NASDAQ:CLBT)?

Oct 30
Is There Now An Opportunity In Cellebrite DI Ltd. (NASDAQ:CLBT)?

There Could Be A Chance Cellebrite DI Ltd.'s (NASDAQ:CLBT) CEO Will Have Their Compensation Increased

Sep 10
There Could Be A Chance Cellebrite DI Ltd.'s (NASDAQ:CLBT) CEO Will Have Their Compensation Increased

Cellebrite: Rating Downgrade As Valuation Has Caught Up

Aug 27

Cellebrite DI Ltd.'s (NASDAQ:CLBT) 29% Share Price Surge Not Quite Adding Up

Aug 17
Cellebrite DI Ltd.'s (NASDAQ:CLBT) 29% Share Price Surge Not Quite Adding Up

Opbrengsten en kosten

Hoe Cellebrite DI geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:CLBT Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
31 Dec 2547678220114
30 Sep 2545676212110
30 Jun 25437-151197107
31 Mar 25419-194190102
31 Dec 24401-28318398
30 Sep 24385-31717595
30 Jun 24362-10316689
31 Mar 24343-11216186
31 Dec 23325-8115484
30 Sep 23306-6414582
30 Jun 23294-4214584
31 Mar 232802014282
31 Dec 2227111613881
30 Sep 2226516513880
30 Jun 2225915214275
31 Mar 2225512213270
31 Dec 212467012466
30 Sep 21236711861
30 Jun 2122379858
31 Mar 2120929656
31 Dec 20195-99254
31 Dec 19172-109147

Kwaliteitswinsten: CLBT heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: CLBT is in het verleden winstgevend geweest.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: CLBT is de afgelopen 5 jaar winstgevend geworden en heeft de winst met -39.1% per jaar laten groeien.

Versnelling van de groei: CLBT is het afgelopen jaar winstgevend geworden, waardoor de winstgroei moeilijk te vergelijken is met het 5-jarig gemiddelde.

Winst versus industrie: CLBT is het afgelopen jaar winstgevend geworden, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Software -sector ( 16% ).

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 16.2% ) van CLBT wordt als laag beschouwd.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/04/29 19:25
Aandelenkoers aan het einde van de dag2026/04/29 00:00
Inkomsten2025/12/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Cellebrite DI Ltd. wordt gevolgd door 9 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Tyler RadkeCitigroup Inc
Jeffrey Van RheeCraig-Hallum Capital Group LLC
Bhavin ShahDeutsche Bank